Better Preclinical Models. Better Predictions. Better Patient Response.
Tumor Models gives you the tools to develop and utilize the very best preclinical oncology models.
This is a meeting for drug developers who are looking for answers to the difficulties faced with preclinical oncology models that are currently being used to test new cancer drugs. This is a forum to learn what you really need to know about the models pharma are using that are superior in predicting efficacy and mimicking tumor activity in patients. It’s also the best way to identify what preclinical questions need to be answered and make the best possible translational decisions. Decisions that will lead to more effective drug performance in the clinic.
Distinguished Professor, UC San Diego
Napoleone is credited with identifying the human VEGF gene and describing its proangiogenic properties, which formed the basis for the development of Genentech’s bevacizumab. In 2013 he was awarded the $3 million Breakthrough Prize in Life Sciences for his work
Director of in vivo Pharmacology, EMD Serono
Laboratory Head, Sanofi
Principal Scientist, AstraZeneca
Senior Scientist, Millennium Pharmaceuticals
Postdoctoral Fellow, Pfizer
Senior Research Investigator, Novartis
Senior Director, Merrimack Pharmaceuticals
Jonathan leads the pre-POC team for MM-398, liposomal irinotecan, charged with the
Ching Ching Leow
Senior Scientist, MedImmune
Principle Scientist, Eisai
Head of Cancer Modeling, NIH
Director of Research, Jounce Therapeutics
Senior Research Biologist, Merck
Professor of Biology, Boston College
Senior Research Director, Momenta Pharmaceuticals
Senior Scientist, Pfizer
Terri Van Dyke
Head of Cancer Pathways & Mechanisms, NIH
Terry, a leader in the use and study of genetically modified mice to model human disease, serves as Chief of the Mouse Cancer Genetics Program and Director of the Center for Advanced Preclinical Research at the NCI.
Research Director, Roche
Li has worked as a Research Director and DMPK expert at Hoffmann-La Roche. She has contributed to many oncology programs from discovery to final registration including VELCADE, ZELBORAF and Obinutuzumab.
Associate Director, EMD Serono
Corporate Vice President
Global Discovery Research Services, Charles River Laboratories
DOWNLOAD BROCHURE here
MEETING WEBSITE: http://tumor-models.com/